EUVIMEDOpdag EUVIMED
Open access · CC BY-NC-ND 4.0

Association of BKV viremia and nephropathy with adverse alloimmune outcomes in kidney transplant recipients

Christie Rampersad iD, Chris Wiebe iD, Robert Balshaw, Jared Bullard, Ian W Gibson, Aaron Trachtenberg iD, James Shaw, Armelle Perez Cortes Villalobos, Martin Karpinski, Aviva Goldberg, Patricia Birk, Maury Pinsk iD and 3 more

Clinical Transplantation · 2024-05 · 38 (5)

DOI: 10.1111/ctr.15329 ↗

At a glance

Journal article in Clinical Transplantation, published online on 2024-05-09. Written by Christie Rampersad and 14 co-authors. Institution: University Health Network, University of Toronto, Toronto, Ontario, Canada. Major MEDLINE topics: Kidney Transplantation, BK Virus, Polyomavirus Infections, Graft Survival. Cited 10 times so far (Crossref); 40 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: CIHR, Canadian Institutes of Health Research.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

Immunosuppression reduction for BK polyoma virus (BKV) must be balanced against risk of adverse alloimmune outcomes. We sought to characterize risk of alloimmune events after BKV within context of HLA‐DR/DQ molecular mismatch (mMM) risk score.

Methods

This single‐center study evaluated 460 kidney transplant patients on tacrolimus‐mycophenolate‐prednisone from 2010‐2021. BKV status was classified at 6‐months post‐transplant as “BKV” or “no BKV” in landmark analysis. Primary outcome was T‐cell mediated rejection (TCMR). Secondary outcomes included all‐cause graft failure (ACGF), death‐censored graft failure (DCGF), de novo donor specific antibody (dnDSA), and antibody‐mediated rejection (ABMR). Predictors of outcomes were assessed in Cox proportional hazards models including BKV status and alloimmune risk defined by recipient age and molecular mismatch (RAMM) groups.

Results

At 6‐months post‐transplant, 72 patients had BKV and 388 had no BKV. TCMR occurred in 86 recipients, including 27.8% with BKV and 17% with no BKV ( p = .05). TCMR risk was increased in recipients with BKV (HR 1.90, (95% CI 1.14, 3.17); p = .01) and high vs. low‐risk RAMM group risk (HR 2.26 (95% CI 1.02, 4.98); p = .02) in multivariable analyses; but not HLA serological MM in sensitivity analysis. Recipients with BKV experienced increased dnDSA in univariable analysis, and there was no association with ABMR, DCGF, or ACGF.

Conclusions

Recipients with BKV had increased risk of TCMR independent of induction immunosuppression and conventional alloimmune risk measures. Recipients with high‐risk RAMM experienced increased TCMR risk. Future studies on optimizing immunosuppression for BKV should explore nuanced risk stratification and may consider novel measures of alloimmune risk.

Subjects

MeSH terms (MEDLINE)

Kidney TransplantationBK VirusPolyomavirus InfectionsGraft SurvivalGraft RejectionTumor Virus InfectionsViremiaKidney Function TestsHumansFemaleMaleMiddle AgedFollow-Up StudiesPrognosisRisk FactorsGlomerular Filtration RateAdultPostoperative ComplicationsImmunosuppressive AgentsRetrospective StudiesKidney Failure, ChronicKidney DiseasesTransplant Recipients

Author keywords

HLA eplet mismatchT‐cell mediated rejectionalloimmune riskantibody‐mediated rejectionbiopsy‐proven acute rejectiondeath‐censored graft survivaldonor specific antibodygraft survivalkidney transplantpolyoma virus

Substances

Immunosuppressive Agents

Authors and institutions

  • University Health Network, University of Toronto, Toronto, Ontario, Canada.
  • Transplant Manitoba Adult Kidney Program, Winnipeg, Manitoba, Canada.
  • Department of Internal Medicine, University of Manitoba, Winnipeg, Manitoba, Canada.
  • George and Fay Yee Centre for Healthcare Innovation, Winnipeg, Manitoba, Canada.
  • Cadham Provincial Laboratory, Winnipeg, Manitoba, Canada.
  • Department of Pediatrics, University of Manitoba, Winnipeg, Manitoba, Canada.

ORCID profiles: Christie Rampersad, Chris Wiebe, Aaron Trachtenberg, Maury Pinsk, David N Rush, Peter W Nickerson, Julie Ho

Funding

  • CIHR
  • Canadian Institutes of Health Research

Cite

APA

Rampersad, C., Wiebe, C., Balshaw, R., Bullard, J., Gibson, I. W., Trachtenberg, A., Shaw, J., Villalobos, A. P. C., Karpinski, M., Goldberg, A., Birk, P., Pinsk, M., Rush, D. N., Nickerson, P. W., & Ho, J. (2024). Association of BKV viremia and nephropathy with adverse alloimmune outcomes in kidney transplant recipients. Clinical Transplantation, 38(5). https://doi.org/10.1111/ctr.15329

Vancouver

Rampersad C, Wiebe C, Balshaw R, Bullard J, Gibson IW, Trachtenberg A, et al. Association of BKV viremia and nephropathy with adverse alloimmune outcomes in kidney transplant recipients. Clinical Transplantation. 2024;38(5). doi:10.1111/ctr.15329

BibTeX
@article{Rampersad2024,
  author = {Rampersad, Christie and Wiebe, Chris and Balshaw, Robert and Bullard, Jared and Gibson, Ian W and Trachtenberg, Aaron and Shaw, James and Villalobos, Armelle Perez Cortes and Karpinski, Martin and Goldberg, Aviva and Birk, Patricia and Pinsk, Maury and Rush, David N and Nickerson, Peter W and Ho, Julie},
  title = {Association of BKV viremia and nephropathy with adverse alloimmune outcomes in kidney transplant recipients},
  journal = {Clinical Transplantation},
  year = {2024},
  volume = {38},
  number = {5},
  doi = {10.1111/ctr.15329}
}
Start for free →